“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer. 

This is the fourth story in a series that marks the 20th anniversary of the publication of papers on the role of EGFR mutation in lung cancer. This multimedia series is guest-edited by Suresh S. Ramalingam, a lung cancer expert, executive director of Winship Cancer Institute of Emory University, and editor-in-chief of the journal Cancer. The series explores the process of discovery of EGFR mutations in lung cancer, the learning curve for using the drugs that target those mutations, and the unparalleled impact on patients with lung cancer and other diseases.

“Most of my memories of her are of her being in some form of treatment,” said Erickson, who is currently a stay-at-home mom of two teenagers in Macon, Georgia. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login